GME751 clinical trials

A PK Study to Compare GME751 (Proposed Pembrolizumab Biosimilar) and US-licensed and EU-authorized Keytruda® in Participants With Stage II and III Melanoma

This study compares a new medicine called GME751 to an existing treatment, Keytruda, for people with melanoma that has been removed by surgery. It checks if GME751 works similarly and is safe.